These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

29 related articles for article (PubMed ID: 20595600)

  • 1. Point: The Need for Additional FDA Regulations in Laboratory Medicine.
    Konnick EQ
    J Appl Lab Med; 2024 Jan; 9(1):151-154. PubMed ID: 38167766
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA Announces Increased Oversight of Some Diagnostic Laboratory Tests.
    Harris E
    JAMA; 2024 Jun; 331(24):2071. PubMed ID: 38819803
    [No Abstract]   [Full Text] [Related]  

  • 3. Counterpoint: Why the FDA Should Not Regulate Laboratory-Developed Tests.
    Leung ML
    J Appl Lab Med; 2024 Jan; 9(1):155-158. PubMed ID: 38167755
    [No Abstract]   [Full Text] [Related]  

  • 4. US Food and Drug Administration embraces using innovation to identify optimized dosages for patients with cancer.
    Shord SS; Zhu H; Liu J; Rahman A; Booth B; Zineh I
    CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1573-1576. PubMed ID: 37641498
    [No Abstract]   [Full Text] [Related]  

  • 5. Bis-biguanide dihydrochloride inhibits intracellular replication of M. tuberculosis and controls infection in mice.
    Shen H; Wang F; Zeng G; Shen L; Cheng H; Huang D; Wang R; Rong L; Chen ZW
    Sci Rep; 2016 Sep; 6():32725. PubMed ID: 27601302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans.
    Kim K; Zilbermintz L; Martchenko M
    Ann Clin Microbiol Antimicrob; 2015 Jun; 14():32. PubMed ID: 26054754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors.
    Siles SA; Srinivasan A; Pierce CG; Lopez-Ribot JL; Ramasubramanian AK
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3681-7. PubMed ID: 23689719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed-cisplatin combination in mesothelioma.
    Reck M; Gatzemeier U
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):231-7. PubMed ID: 15877521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA regulations for drug development.
    Behrman RE; Woodcock J
    Science; 2010 Jul; 329(5987):33; author reply 33. PubMed ID: 20595600
    [No Abstract]   [Full Text] [Related]  

  • 10. Cancer therapy reform.
    Levinson AD
    Science; 2010 Apr; 328(5975):137. PubMed ID: 20378778
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeted agents: the rules of combination.
    Kwak EL; Clark JW; Chabner B
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5232-7. PubMed ID: 17875749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recasting cancer trials.
    Nat Biotechnol; 2012 Jul; 30(7):567. PubMed ID: 22781659
    [No Abstract]   [Full Text] [Related]  

  • 13. Long overdue: phase II studies in older cancer patients: where does the FDA stand?
    Balducci L; Tam-McDevitt J; Hauser R; Simon J
    J Clin Oncol; 2008 Mar; 26(8):1387-88. PubMed ID: 18323564
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug approved for late-stage cervical cancer.
    FDA Consum; 2006; 40(5):8. PubMed ID: 17326305
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.